Cognition Therapeutics’ Stock Plummets After Alzheimer’s Drug Misses Cognitive Endpoint

1. Stock Decline: Cognition Therapeutics' stock plummeted nearly 43% after the company's Alzheimer's drug, CT-1812, missed its cognitive endpoint in a clinical trial.
2. Phase 2 Data: The Phase 2 data showed an early drug effect that lessened over time, leading to the stock decline.
3. Endpoint Miss: The drug failed to meet its key efficacy goal in the trial, causing the stock to tumble.
4. Next Stage: Despite the endpoint miss, Cognition Therapeutics plans to move forward with the next stage of clinical testing for CT-1812.
5. Oral Treatment: CT-1812 is an oral, small-molecule candidate being developed for mild to moderate Alzheimer's disease.